Form 4: Edwards Lifesciences Executive Daniel J. Lippis Reports Stock Transactions

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports the acquisition and disposal of common stock on July 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 11, 2024, Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reported transactions involving the company's common stock.
• The transactions included the acquisition of 500 shares at $45.2767 per share and the disposal of 500 shares at $94.18 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 11, 2023.
• Following these transactions, Lippis beneficially owns 23,189.0651 shares of Edwards Lifesciences common stock directly.
• Lippis also holds options to acquire 4,530 shares of common stock at an exercise price of $45.2767, which were granted on May 17, 2019, and expire on May 16, 2025.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their trading activities. The use of a 10b5-1 plan is a common practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The filing is standard practice for corporate insiders and aligns with SEC regulations.
• The use of a 10b5-1 trading plan is a common and accepted method for executives to manage their stock transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in beneficial ownership, but the overall effect is likely minimal given the relatively small number of shares involved.

Key Dates